메뉴 건너뛰기
Journal of Thoracic Oncology
Volumn 7, Issue 5, 2012, Pages 941-942
Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases
Author keywords

[No Author keywords available]
Indexed keywords

CISPLATIN; GEFITINIB; PEMETREXED;
EID: 84862120443     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31825134ac     Document Type: Letter
Times cited : (13)
References (7)
  • 1
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 2
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
    • (2005) PLoS Med , vol.2
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3
  • 3
    • 80054931335 scopus 로고    scopus 로고
    • Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations
    • De Pas T, Toffalorio F, Manzotti M, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6:1895-1901.
    • (2011) J Thorac Oncol , vol.6 , pp. 1895-1901
    • De Pas, T.1    Toffalorio, F.2    Manzotti, M.3
  • 4
    • 79957916527 scopus 로고    scopus 로고
    • Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer
    • Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
    • (2011) Clin Cancer Res , vol.17 , pp. 3812-3821
    • Wu, J.Y.1    Yu, C.J.2    Chang, Y.C.3    Yang, C.H.4    Shih, J.Y.5    Yang, P.C.6
  • 5
    • 59449097754 scopus 로고    scopus 로고
    • Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy
    • Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15:460-467.
    • (2009) Clin Cancer Res , vol.15 , pp. 460-467
    • Kancha, R.K.1    Von Bubnoff, N.2    Peschel, C.3    Duyster, J.4
  • 6
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer - Molecular and clinical predictors of outcome
    • Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
    • (2005) N Engl J Med , vol.353 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3
  • 7
    • 15744372810 scopus 로고    scopus 로고
    • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    • Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17
    • (2005) PLoS Med , vol.2
    • Pao, W.1    Wang, T.Y.2    Riely, G.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.